Prudential Financial
ZNTL icon

Prudential Financial’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Prudential Financial’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20,850
Closed -$48.8K – 2603
2026
Q1 		$48.8K Sell
20,850
-3,700
-15% -$9.55K ﹤0.01% 2319
2025
Q4 		$33.1K Buy
24,550
+2,950
+14% +$4.29K ﹤0.01% 2171
2025
Q3 		$32.6K Buy
21,600
+2,700
+14% +$4.05K ﹤0.01% 2379
2025
Q2 		$21.9K Sell
18,900
-13,070
-41% -$17.2K ﹤0.01% 2398
2025
Q1 		$50.8K Buy
31,970
+19,130
+149% +$41.3K ﹤0.01% 2200
2024
Q4 		$38.9K Buy
+12,840
New +$42.1K ﹤0.01% 2234
2022
Q1 		– Sell
-2,775
Closed -$233K – 2710
2021
Q4 		$233K Buy
+2,775
New +$215K ﹤0.01% 2491

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Prudential Financial's ZNTL Position: Q2 2026 in Review

Prudential Financial sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2026, closing a stake of 20,850 shares — an estimated $48.8K sold.

Prudential Financial first reported a position in ZNTL in Q4 2021 and held it in 7 quarters. The position peaked at $233K in Q4 2021. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Prudential Financial reported no remaining Zentalis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Prudential Financial sold 20,850 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $48.8K.
  • Prudential Financial first reported a position in Zentalis Pharmaceuticals in Q4 2021 and held it in 7 quarters.
  • Prudential Financial's Zentalis Pharmaceuticals position peaked at $233K in Q4 2021.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.